Intrinsiqq
Arcus Biosciences Inc. logo

Arcus Biosciences Inc.

RCUS

Compare
⚠ Showing the latest available close (Nov 9, 2026, 2 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$2.73B
EPS-$3.62
P/E-5.23
P/FCF-5.86
EV/EBITDA-4.66
FCF Yield–
Div. Yield–
Net Debt/FCF1.1x
Arcus Biosciences Inc. intrinsic value
52-Week Range
$17.69$31.57

Profitability & Returns

Revenue (TTM)

$100M

▼ -4.3% YoY

Net Income (TTM)

-$453M

▼ -24.7% YoY

Op. Margin

-475.00%

▼ -28.4pp YoY

ROIC

-59.61%

▲ +1.1pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$466M

▼ -175.0% YoY

Op. Cash Flow (TTM)

-$465M

▼ -183.5% YoY

Net Debt

-$514M

Net Cash Position

Cash & Equiv.

$630M

5Y CAGR: +25.9%

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with RCUS

CompareIntrinsic value
SEPNSepterna, Inc.
$50.74+3.87%25
AGIOAgios Pharmaceuticals Inc.
$31.38+6.70%40
ASRTAssertio Holdings Inc.
$9.10-0.07%10
LFCRLifecore Biomedical, Inc.
$6.38+0.31%21
TBPHTheravance Biopharma Inc.
No recent price82
ETONEton Pharmaceuticals Inc.
$64.33+13.94%75
CYTKCytokinetics, Incorporated
$55.14+2.70%18
LABStandard Biotools Inc.
$0.68-1.72%35

Held by ETFs

RCUS is in 65 US ETFs. The largest of them, with RCUS's weight in each:

Arcus Biosciences (RCUS) in four numbers

Fair value (revenue)
$6.20
Price $18.95 is 206% above it.
Intrinsic Value
Quality score
10/100
Best check: net debt, -$514M. Weakest: return on capital, -59.6%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-5.23
Negative: a loss over the last twelve months. Price to free cash flow -5.86.
Financials

Questions about Arcus Biosciences

Is Arcus Biosciences (RCUS) overvalued?

At $18.95, Arcus Biosciences' price is 206% above the $6.20 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Arcus Biosciences' fair value?

Intrinsiqq's calculator puts Arcus Biosciences' fair value at $6.20 a share. It grows revenue per share 13.9% a year for 5 years, applies an exit P/S of 7.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.65. Every input can be changed on the Intrinsic Value tab.

Is Arcus Biosciences a high-quality business?

Arcus Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$514M, and its weakest is return on capital at -59.6%. The Quality tab shows every check against its target.

Does Arcus Biosciences (RCUS) pay a dividend?

No. Arcus Biosciences (RCUS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 29 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 9 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in RCUS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing RCUS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.